No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NRBO NeuroBo Pharmaceuticals
- 4.4702
- -0.2098-4.48%
Close Jul 3 13:00 ET
- 4.6000
- +0.1298+2.90%
Post 16:54 ET
25.34MMarket Cap-1367P/E (TTM)
4.8000High4.4702Low33.67KVolume4.6000Open4.6800Pre Close156.74KTurnover24.86%Turnover RatioLossP/E (Static)5.67MShares6.749952wk High2.52P/B605.31KFloat Cap2.900052wk Low--Dividend TTM135.41KShs Float129539.9482Historical High--Div YieldTTM7.05%Amplitude2.8880Historical Low4.6550Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Watching NeuroBo Pharmaceuticals; Zacks Small-Cap Research Gives Stock $22 Price Valuation
Express News | NeuroBo Pharmaceuticals Shares Are Trading Higher After the Company Announced the Dosing of the First Patient in the Multiple Ascending Dose Part 2 of Its Phase 1 Clinical Trial of DA-1726
Express News | NeuroBo Pharmaceuticals Inc: Planned Part 3 Interim Data Readout Expected Mid-2026 With Top-Line Data in Second Half of 2026
Express News | NeuroBo Pharmaceuticals: Top-Line Data Readout From Single Ascending Dose Part 1 Expected in Q3 2024 & From Multiple Ascending Dose Part 2 in Q1 2025
NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing...
NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weig
Express News | NeuroBo Pharmaceuticals Doses First Patient in the Mad Part 2 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity
Comments
$NeuroBo Pharmaceuticals(NRBO.US$
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has dosed the first patient in Part 2 of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for obesity treatment. This MAD study, expected to enroll 36 participants, will investigate safety, tolerability, and pharmacokinetics, with top-line data anticipated...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has dosed the first patient in Part 2 of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for obesity treatment. This MAD study, expected to enroll 36 participants, will investigate safety, tolerability, and pharmacokinetics, with top-line data anticipated...
$NeuroBo Pharmaceuticals(NRBO.US$ Top-Line Data Readout From Single Ascending Dose Part 1 Expected in Q3 2024 & From Multiple Ascending Dose Part 2 in Q1 2025![]()
1
$NeuroBo Pharmaceuticals(NRBO.US$
NeuroBo Pharmaceuticals Announces the CLOSING of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NeuroBo Pharmaceuticals Announces the CLOSING of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
1
$NeuroBo Pharmaceuticals(NRBO.US$ Dong-A ST (10%+) Buys 2.54M Shares of NeuroBo Pharmaceuticals at Avg Price of $3.13; Total Value Of $7,964,378.9
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg